About 25% of drug development efforts may target these enzymes [11], and hundreds of protein kinase inhibitors in preclinical and clinical trials worldwide may be effective against neoplasms as well as non-neoplastic diseases, including pulmonary arterial hypertension [12]. Here, WEE1 is linked to pulmonary arterial hypertension.